Amarantus Bioscience (AMBS) Stock Price, News & Analysis

Company Overview

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS) is a development-stage biotechnology company focused on the creation of diagnostic and therapeutic products for neurodegenerative and orphan diseases. By leveraging proprietary platform technologies in protein engineering and cellular biomarkers, the company aims to address conditions with significant unmet medical need and to enable earlier detection and intervention.

Amarantus’s therapeutic portfolio includes MANF, a neurotrophic factor under investigation for its potential to support dopaminergic neuron survival in Parkinson’s disease, and MBS6017, a modified tissue plasminogen activator being developed for the treatment of acute ischemic stroke. In addition, the company is advancing an immuno-oncology T-cell receptor platform targeting select tumor types. On the diagnostics side, the LymPro Test—a blood-based assay designed for early identification of Alzheimer’s disease risk—represents the company’s effort to bring accessible, non-invasive tools to clinicians and patients.

Headquartered in San Francisco, California, Amarantus collaborates with academic institutions, contract research organizations and industry partners to advance its pipeline through preclinical studies and clinical trials. The company’s leadership team combines expertise in drug development, regulatory affairs and commercial strategy, positioning Amarantus to navigate the complex path toward regulatory clearance and potential market introduction of its novel products.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 49,301 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMBS Stock Analysis - Frequently Asked Questions

How do I buy shares of Amarantus Bioscience?

Shares of AMBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarantus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarantus Bioscience investors own include Aurora Cannabis (ACB), B2Gold (BTG), CEA Industries (CEAD), Fortune Minerals (FTMDF), Kutcho Copper (KCCFF), Liberty Star Uranium & Metals (LBSR) and Liberty Gold (LGDTF).

Company Calendar

• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AMBS
• CIK: 1424812
• Web: www.amarantus.com
• Phone: (650) 862-5391
• Fax: 408-852-4427
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.88